Modified-Release Gamma-Hydroxybutyrate for Once-Nightly Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modified release formulations of gamma-hydroxybutyrate suffer from low bioavailability and inconvenience due to the need for multiple doses and high sodium intake, failing to approximate the pharmacokinetic profile of twice-nightly immediate release sodium oxybate administration.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer pH 6.8, achieving bioavailability comparable to twice-nightly immediate release sodium oxybate across a range of therapeutic doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of gamma-hydroxybutyrate are used, then the convenience of administration is improved (once-nightly dosing), but the bioavailability is reduced compared to immediate release formulations
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion that rapidly releases gamma-hydroxybutyrate upon contact with gastric acid, and a modified release portion that releases the remaining dose more slowly in the intestinal tract. This segmentation allows the drug to achieve both rapid initial absorption (improving bioavailability) and sustained release over time (enabling once-nightly dosing convenience).
Solution Approach 2:
The invention changes the release parameters of gamma-hydroxybutyrate by using different dissolution media characteristics (pH 1.2 gastric simulation vs. pH 6.8 intestinal simulation). The formulation is designed to release 20-80% of the dose in the acidic environment and the remaining 20-80% in the neutral-to-alkaline environment, thereby optimizing both bioavailability and dosing convenience across different gastrointestinal conditions.
2Reliability
If immediate release sodium oxybate is administered twice nightly, then the pharmacokinetic profile is optimized, but the complexity of dosing regimen increases
Solution Approach 1:
The invention merges the functions of two separate immediate release doses into a single modified release formulation. The immediate release portion provides the first dose effect, while the modified release portion sustains the effect throughout the night, eliminating the need for a second dose and simplifying the dosing regimen while maintaining pharmacokinetic efficacy.
Solution Approach 2:
The formulation performs preliminary action by releasing a significant portion (20-80%) of the gamma-hydroxybutyrate in the acidic gastric environment before the drug reaches the intestinal tract. This preliminary release ensures rapid initial absorption and therapeutic effect, while the remaining portion is released later in the intestinal phase to sustain the effect, thereby replicating the pharmacokinetic profile of multiple doses in a single administration.
3Reliability
If high doses of gamma-hydroxybutyrate are administered, then the therapeutic effectiveness is improved, but the adverse reactions increase
Solution Approach 1:
The formulation implements periodic action by releasing gamma-hydroxybutyrate in two distinct phases: an initial rapid release phase in the stomach providing immediate therapeutic effect, followed by a sustained release phase in the intestine maintaining therapeutic levels throughout the night. This periodic release pattern achieves effective therapeutic coverage while avoiding the peak concentration-related adverse reactions associated with single large immediate release doses.
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.